5965-53-7Relevant articles and documents
PHOTOINITIATORS FOR LIGHT-CURABLE COMPOSITIONS
-
Paragraph 0069-0072, (2020/08/05)
Compounds of formula (I) are photoinitiators or photosensitizers in a photopolymerizable composition: R1 represents a monovalent, linear, branched or cyclic, aliphatic hydrocarbon group having 1 to 20 carbon atoms, optionally substituted with substituent(s) selected from —Cl, —Br, —OH, ═O, —NH—CO— OR2, —NH—CO—R2 or free-radically or ionically polymerizable groups. Each R2 is independently —H or C1-6 alkyl; n is ≥1. If n=1, Z and Y are absent and X represents —OR3; if n is >1, Z represents —OR4—, Y represents —ORs— and X represents —H or —OH. R3 represents —H or R1; and R4 and R5 each independently represent a bivalent hydrocarbon group. The polymerizable moieties as optional substituents of R1 are polymerizable double or triple bonds, lactam, lactone and epoxide moieties, which are subjectable to ring-opening polymerization; and two of R1 to R5 may be linked to one another to form a ring or a dimer.
Preparation method of 2- diethyl-1,5- n-pentanedioic acid diethyl ester (by machine translation)
-
Paragraph 0010-0022, (2019/12/02)
The reaction liquid is mixed uniformly, 2 - and then the reaction solution is stirred and reacted at a normal temperature, and the reaction solution Amberlyst - 15 is filtered 2 - 2 - and concentrated to obtain diethyl-ethyl-diformate 2 - 15:1~1.2 Amberlyst - 15 2 - 1:2~2.2. The preparation method is mild in reaction condition, safe and simple in preparation process and purification steps, high in product yield and convenient to realize industrialization. (by machine translation)
Identification and Structure-Activity Relationship of HDAC6 Zinc-Finger Ubiquitin Binding Domain Inhibitors
Ferreira De Freitas, Renato,Harding, Rachel J.,Franzoni, Ivan,Ravichandran, Mani,Mann, Mandeep K.,Ouyang, Hui,Lautens, Mark,Santhakumar, Vijayaratnam,Arrowsmith, Cheryl H.,Schapira, Matthieu
supporting information, p. 4517 - 4527 (2018/05/31)
HDAC6 plays a central role in the recruitment of protein aggregates for lysosomal degradation and is a promising target for combination therapy with proteasome inhibitors in multiple myeloma. Pharmacologically displacing ubiquitin from the zinc-finger ubiquitin-binding domain (ZnF-UBD) of HDAC6 is an underexplored alternative to catalytic inhibition. Here, we present the discovery of an HDAC6 ZnF-UBD-focused chemical series and its progression from virtual screening hits to low micromolar inhibitors. A carboxylate mimicking the C-terminal extremity of ubiquitin, and an extended aromatic system stacking with W1182 and R1155, are necessary for activity. One of the compounds induced a conformational remodeling of the binding site where the primary binding pocket opens up onto a ligand-able secondary pocket that may be exploited to increase potency. The preliminary structure-activity relationship accompanied by nine crystal structures should enable further optimization into a chemical probe to investigate the merit of targeting the ZnF-UBD of HDAC6 in multiple myeloma and other diseases.
